Drug profile · INN
vernakalant hydrochloride
BRINAVESS
vernakalant hydrochloride (BRINAVESS) is a voltage-gated potassium channel subunit kv1.5 blocker.
EMA: approved Cardiovascular system (C01) C01BG11
Patents linked 0
Pipeline programs 0
News articles 0
Drug details — vernakalant hydrochloride
- Class
- Cardiovascular system (C01)
- Route
- —
- Patents
- 0
- Programs
- 0
- Data quality
- 0.83
Quick answer
vernakalant hydrochloride (BRINAVESS) is a voltage-gated potassium channel subunit kv1.5 blocker.
Key facts
INN vernakalant hydrochloride
Brand BRINAVESS
Mechanism Voltage-gated potassium channel subunit Kv1.5 blocker
Target Voltage-gated inwardly rectifying potassium channel KCNH2
Therapeutic class Cardiovascular system (C01)
ATC code C01BG11
Mechanism of action
Voltage-gated potassium channel subunit Kv1.5 blocker
Primary target: Voltage-gated inwardly rectifying potassium channel KCNH2
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Related & competitor drugs
Frequently asked questions
What is vernakalant hydrochloride?
vernakalant hydrochloride (BRINAVESS) is a voltage-gated potassium channel subunit kv1.5 blocker.
What is the brand name for vernakalant hydrochloride?
BRINAVESS is a marketed brand name for vernakalant hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.